


SUPPLEMENTARY MATERIAL

Post-marketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12-39 years in Italy: a multi-database, self-controlled case series study

Massari M & Spila Alegiani S et al.

Figure S1- Diagram showing the data flow when using *TheShinISS* to locally elaborate health care data structured according to a Common Data Model.



CDM: Common Data Model

Table S1. Definition of study comorbidities.

Comorbidities	Databases		
	Hospital discharge	Pharmacy claims	Copayment exemption
	ICD 9-CM codes (in the last 5 years)	ATC codes (in the last 12 months)	Exemption codes
COPD	490; 492; 493; 494; 496	R03	057; 007
Chronic pulmonary disease	480-488; 491; 495; 518.81-518.84	J05AH	024
Chronic kidney failure	580; 582-585; 593; 753.12-753.14		023; 022; 061; 062
Neoplasms	140-209, V10	L01	048
Diabetes mellitus	250	A10	013
Hematologic disease	280-284; 285 (excl.285.1); 286-289	B01AA; B01AB; B01AE; B01AF; B01AX; B02BD; B03	003
Cardiovascular and cerebrovascular diseases	390-398; 406-459	B01AC; C01B; C01DA; C08DA; C08DB	002; 021 0A02; 0B02; 0C02; 036
Hypertension	401-405	C02; C03; C07; C08 (excl. C08DA; C08DB); C09	031; 0A31; 0031
Hepatopathy	456.0-456.2; 571-572; 573.0		008; 016
Dementia /Alzheimer	290; 294.1; 331.2	N06DA, N06DX	011; 029
HIV	042	J05AE; J05AF; J05AG; J05AR	020
Rheumatic diseases	446.5; 710; 714; 720; 725; 696	L04	006;028; 030; 045; 054; 067
Cystic fibrosis	277.0	R07AX	018
Neurological diseases	296.3; 238.7; 311; 332; 340; 345; 348.39	N03A; N04B; N05A; N06A	017; 038; 044; 046
Peptic Ulcer	531-533	A02B	
Colitis	555; 556		009
Celiac disease	579.0		059
Infection (in the last 12 months)	053; 599.0; 010-018; 031; 078.5; 052-054; 136.3; 117.5	J01; J02; J04; J05 (excl. J05AE; J05AF; J05AG; J05AR; J05AH)	055
Corticosteroids for systemic use		H02A	
NSAIDs use		M01A	
Estropogestinics use		G03	

ICD: International Classification of Disease; ATC: Anatomical Therapeutic Chemical Classification System; COPD: Chronic obstructive pulmonary disease; HIV: Human Immunodeficiency Virus; NSAIDs: Non-steroidal anti-inflammatory drugs

Table S2 - Relative incidence estimated by adjusted SCCS and excess cases per 100,000 vaccinated by risk intervals: 232 myocarditis and/or pericarditis events in the BNT162b2 vaccinated males aged 12-39 years from 27 December 2020 to 30 September 2021.

Risk interval	Dose	Events in the risk interval (n)	Adjusted Relative Incidence (95% CI)*	Excess cases per 100,000 vaccinated (95% CI)**
[0-7)	Dose 1	9	1.53 (0.71-3.31)	
	Dose 2	13	3.45 (1.78-6.68)	1.0 (0.6-1.2)
[7-14)	Dose 1	9	1.53 (0.74-3.17)	
	Dose 2	4	1.01 (0.37-2.75)	
[14-21)	Dose 1	8	1.41 (0.63-3.14)	
	Dose 2	5	1.29 (0.49-3.42)	
Ref.		184	1.0	

SCCS: Self-Controlled Cases Series; n.: number; CI: Confidence interval; Ref.: reference period (unexposed period). *adjusted by calendar period; **excess cases are not given when RI did not show a statistically significant increase of incidence over the [0-21) risk interval

Table S3 - Relative incidence estimated by adjusted SCCS and excess cases per 100,000 vaccinated by risk intervals: 114 myocarditis and/or pericarditis events in the BNT162b2 vaccinated females aged 12-39 years from 27 December 2020 to 30 September 2021.

Risk interval	Dose	Events in the risk interval (n)	Adjusted Relative Incidence (95% CI)*	Excess cases per 100,000 vaccinated (95% CI)**
[0-7)	Dose 1	5	0.88 (0.34-2.32)	
	Dose 2	9	3.38 (1.47-7.74)	0.7 (0.3-0.9)
[7-14)	Dose 1	1	0.19 (0.02-1.63)	
	Dose 2	3	1.16 (0.35-3.85)	
[14-21)	Dose 1	3	0.71 (0.21-2.44)	
	Dose 2	5	2.01 (0.72-5.62)	
Ref.		88	1.0	

SCCS: Self-Controlled Cases Series; n.: number; CI: Confidence interval; Ref.: reference period (unexposed period). *adjusted by calendar period; **excess cases are not given when RI did not show a statistically significant increase of incidence over the [0-21) risk interval

Table S4 - Relative incidence estimated by adjusted SCCS and excess cases per 100,000 vaccinated by risk intervals: 46 myocarditis and/or pericarditis events in the BNT162b2 vaccinated population aged 12-17 years from 27 December 2020 to 30 September 2021.

Risk interval	Dose	Events in the risk interval (n)	Adjusted Relative Incidence (95% CI)*	Excess cases per 100,000 vaccinated (95% CI)**
[0-7)	Dose 1	3	1.06 (0.17-6.59)	
	Dose 2	7	5.74 (1.52-21.72)	1.7 (0.7-1.9)
[7-14)	Dose 1	3	0.99 (0.24-4.19)	
	Dose 2	1	0.74 (0.11-5.15)	
[14-21)	Dose 1	1	0.36 (0.05-2.72)	
	Dose 2	0	—	
Ref.		31	1.0	

SCCS: Self-Controlled Cases Series; n.: number; CI: Confidence interval; Ref.: reference period (unexposed period). *adjusted by calendar period; **excess cases are not given when RI did not show a statistically significant increase of incidence over the [0-21) risk interval

Table S5 - Relative incidence estimated by adjusted SCCS and excess cases per 100,000 vaccinated by risk intervals: 154 myocarditis and/or pericarditis events in the BNT162b2 vaccinated population aged 18-29 years from 27 December 2020 to 30 September 2021.

Risk interval	Dose	Events in the risk interval (n)	Adjusted Relative Incidence (95% CI)*	Excess cases per 100,000 vaccinated (95% CI)**
[0-7)	Dose 1	7	1.76 (0.76-4.05)	
	Dose 2	11	4.02 (1.81-8.91)	1.1 (0.6-1.3)
[7-14)	Dose 1	3	0.72 (0.20-2.61)	
	Dose 2	4	1.46 (0.51-4.14)	
[14-21)	Dose 1	4	1.00 (0.34-2.96)	
	Dose 2	4	1.56 (0.55-4.44)	
Ref.		121	1.0	

SCCS: Self-Controlled Cases Series; n.: number; CI: Confidence interval; Ref.: reference period (unexposed period). *adjusted by calendar period; **excess cases are not given when RI did not show a statistically significant increase of incidence over the [0-21) risk interval

Table S6 - Relative incidence estimated by adjusted SCCS and excess cases per 100,000 vaccinated by risk intervals: 146 myocarditis and/or pericarditis events in the BNT162b2 vaccinated population aged 30-39 years from 27 December 2020 to 30 September 2021.

Risk interval	Dose	Events in the risk interval (n)	Adjusted Relative Incidence (95% CI)*	Excess cases per 100,000 vaccinated (95% CI)**
[0-7)	Dose 1	4	0.86 (0.31-2.38)	
	Dose 2	4	1.64 (0.59-4.53)	
[7-14)	Dose 1	4	0.97 (0.34-2.80)	
	Dose 2	2	0.84 (0.21-3.38)	
[14-21)	Dose 1	6	1.68 (0.70-4.04)	
	Dose 2	6	2.50 (0.97-6.45)	
Ref.		120	1.0	

SCCS: Self-Controlled Cases Series; n.: number; CI: Confidence interval; Ref.: reference period (unexposed period). *adjusted by calendar period; **excess cases are not given when RI did not show a statistically significant increase of incidence over the [0-21) risk interval

Table S7 - Relative incidence estimated by adjusted SCCS and excess cases per 100,000 vaccinated by risk intervals: 70 myocarditis and/or pericarditis events in the mRNA-1273 vaccinated males aged 12-39 years from 27 December 2020 to 30 September 2021.

Risk interval	Dose	Events in the risk interval (n)	Adjusted Relative Incidence (95% CI)*	Excess cases per 100,000 vaccinated (95% CI)**
[0-7)	Dose 1	10	12.28 (4.09-36.83)	3.8 (3.1-4.0)
	Dose 2	19	11.91 (3.88-36.53)	8.8 (7.2-9.4)
[7-14)	Dose 1	2	2.19 (0.42-11.41)	—
	Dose 2	0	—	—
[14-21)	Dose 1	0	—	—
	Dose 2	1	0.65 (0.08-5.37)	—
Ref.		38	1.0	—

SCCS: Self-Controlled Cases Series; n.: number; CI: Confidence interval; Ref.: reference period (unexposed period). *adjusted by calendar period; **excess cases are not given when RI did not show a statistically significant increase of incidence over the [0-21) risk interval

Table S8 - Relative incidence estimated by adjusted SCCS and excess cases per 100,000 vaccinated by risk intervals: 25 myocarditis and/or pericarditis events in the mRNA-1273 vaccinated females aged 12-39 years from 27 December 2020 to 30 September 2021.

Risk interval	Dose	Events in the risk interval (n)	Adjusted Relative Incidence (95% CI)*	Excess cases per 100,000 vaccinated (95% CI)**
[0-7)	Dose 1	1	0.69 (0.08-5.75)	—
	Dose 2	4	2.08 (0.45-9.72)	—
[7-14)	Dose 1	1	0.69 (0.10-4.87)	—
	Dose 2	0	—	—
[14-21)	Dose 1	1	0.69 (0.07-6.86)	—
	Dose 2	1	0.72 (0.13-4.05)	—
Ref.		17	1.0	—

SCCS: Self-Controlled Cases Series; n.: number; CI: Confidence interval; Ref.: reference period (unexposed period). *adjusted by calendar period; **excess cases are not given when RI did not show a statistically significant increase of incidence over the [0-21) risk interval

Table S9 - Relative incidence estimated by adjusted SCCS and excess cases per 100,000 vaccinated by risk intervals: 11 myocarditis and/or pericarditis events in the mRNA-1273 vaccinated population aged 12-17 years from 27 December 2020 to 30 September 2021.

Risk interval	Dose	Events in the risk interval (n)	Adjusted Relative Incidence (95% CI)*§	Excess cases per 100,000 vaccinated (95% CI)**
[0-7)	Dose 1	0	—	—
	Dose 2	3	—	—
[7-14)	Dose 1	0	—	—
	Dose 2	0	—	—
[14-21)	Dose 1	0	—	—
	Dose 2	1	—	—
Ref.		7	—	—

SCCS: Self-Controlled Cases Series; n.: number; CI: Confidence interval; Ref.: reference period (unexposed period). *adjusted by calendar period; **excess cases are not given when RI did not show a statistically significant increase of incidence over the [0-21) risk interval; §considering the small number of cases in this age group, it was not possible to provide any estimates.

Table S10 - Relative incidence estimated by adjusted SCCS and excess cases per 100,000 vaccinated by risk intervals: 57 myocarditis and/or pericarditis events in the mRNA-1273 vaccinated population aged 18-29 years from 27 December 2020 to 30 September 2021.

Risk interval	Dose	Events in the risk interval (n)	Adjusted Relative Incidence (95% CI)*	Excess cases per 100,000 vaccinated (95% CI)**
[0-7)	Dose 1	9	7.58 (2.62-21.94)	3.5 (2.4-3.8)
	Dose 2	18	9.58 (3.32-27.58)	8.3 (6.7-9.2)
[7-14)	Dose 1	1	0.78 (0.09-6.51)	—
	Dose 2	0	—	—
[14-21)	Dose 1	0	—	—
	Dose 2	1	0.55 (0.07-4.37)	—
Ref.		28	1.0	—


SCCS: Self-Controlled Cases Series; n.: number; CI: Confidence interval; Ref.: reference period (unexposed period). *adjusted by calendar period; **excess cases are not given when RI did not show a statistically significant increase of incidence over the [0-21) risk interval

Table S11 - Relative incidence estimated by adjusted SCCS and excess cases per 100,000 vaccinated by risk intervals: 27 myocarditis and/or pericarditis events in the mRNA-1273 vaccinated population aged 30-39 years from 27 December 2020 to 30 September 2021.

Risk interval	Dose	Events in the risk interval (n)	Adjusted Relative Incidence (95% CI)*	Excess cases per 100,000 vaccinated (95% CI)**
[0-7)	Dose 1	2	6.57 (1.32-32.63)	1.0 (0.3-1.1)
	Dose 2	2	3.22 (0.69-15.10)	—
[7-14)	Dose 1	2	5.87 (1.34-25.74)	1.0 (0.3-1.1)
	Dose 2	0	—	—
[14-21)	Dose 1	1	2.56 (0.23-28.57)	—
	Dose 2	0	—	—
Ref.		20	1.0	—

SCCS: Self-Controlled Cases Series; n.: number; CI: Confidence interval; Ref.: reference period (unexposed period). *adjusted by calendar period; **excess cases are not given when RI did not show a statistically significant increase of incidence over the [0-21) risk interval

Figure S2- Relative Incidence in the [0-7) risk period after mRNA vaccination in the vaccinated population aged 12-39 years from 27 December 2020 to 30 September 2021 by vaccine brand, gender and age group.



RI: Relative Incidence; CI: Confidence Interval; M: Males; F: Females. (*) Considering the small number of cases in the vaccinated with mRNA-1273 of age 12-17 years, it was not possible to provide any estimates

Table S12 – Sensitivity analyses.

	Risk interval	Dose	Adjusted Relative Incidence (95% CI)*	
			BNT162b2	mRNA-1273
Primary analysis	[0-7)	Dose 1	1.27 (0.70-2.31)	6.55 (2.73-15.72)
		Dose 2	3.39 (2.02-5.68)	7.59 (3.26-17.65)
a) SCCS standard SCSS standard cutting the observation time at the first and second dose (n. 441)	[0-7)	Dose 1	1.27 (0.69-2.33)	5.59 (2.37-13.17)
		Dose 2	3.35 (1.98-5.69)	6.20 (2.45-15.68)
b) Observation time period (I) analysis restricted to the study period from 27 December 2020 to 31 May 2021 (n. 85)**	[0-7)	Dose 1	0.48 (0.10-2.20)	***
		Dose 2	3.29 (1.22-8.88)	***
b) Observation time period (II) analysis restricted to the study period from 1 June 2021 to 30 September 2021 (n. 160)**	[0-7)	Dose 1	2.05 (0.97-4.33)	6.26 (2.15-15.22)
		Dose 2	4.32 (2.11-8.83)	13.43 (4.65-38.76)
b) Exposure time period excluding day 0 from [0-7) day risk interval (n. 441)	[0-7)	Dose 1	1.39 (0.75-2.55)	7.68 (3.21-18.39)
		Dose 2	3.96 (2.36-6.62)	8.76 (3.78-20.29)
c) Heterologous vaccination (I) primary analysis excluding individuals with two different brands in the first and second dose (n. 440)	[0-7)	Dose 1	1.27 (0.69-2.31)	6.56 (2.73-15.74)
		Dose 2	3.39 (2.02-5.68)	7.59 (3.26-17.66)
c) Heterologous vaccination (II) censoring 1 subjects who received a different brand on the II dose (from mRNA-1273 to BNT162b2)	[0-7)	Dose 1	***	6.61 (2.75-18.90)
		Dose 2		7.61 (3.27-17.72)
d) SARS-CoV-2 infection restricting the analyses to subjects without a SARS-CoV-2 positive test before and during the study period (n. 378)	[0-7)	Dose 1	1.17 (0.64-2.25)	5.66 (1.99-16.13)
		Dose 2	3.13 (1.82-5.39)	7.85 (3.26-18.94)

SCCS: Self-Controlled Cases Series; CI: Confidence interval. *adjusted by calendar period; **subjects vaccinated and with event in each period were included in this analysis ***considering the small number of cases, it was not possible to provide any estimates

Table S13 -- Relative incidence estimated by adjusted SCCS and excess cases per 100,000 vaccinated by risk intervals: 1,759 myocarditis and/or pericarditis events in the BNT162b2 and 291 events in the mRNA-1273 vaccinated population aged ≥40 years from 27 December 2020 to 30 September 2021 (ancillary analysis).

Gender	Risk interval	Dose	BNT162b2 Vaccinated 6,835,634 (n. cases 1,759)			mRNA-1273 Vaccinated 1,041,582 (n. cases 291)		
			Events in the risk interval (n)	Adjusted Relative Incidence (95% CI)*	Excess cases per 100,000 Vaccinated (95% CI)**	Events in the risk interval (n)	Adjusted Relative Incidence (95% CI)*	Excess cases per 100,000 Vaccinated (95% CI)**
Males+Females	[0-7]	Dose 1	39	0.59 (0.42-0.82)		7	0.56 (0.23-1.36)	
		Dose 2	43	0.84 (0.61-1.16)		10	1.11 (0.57-2.17)	
		Ref.	1,479		1	247	1	
Males	[0-7]	Dose 1	16	0.43 (0.26-0.71)		1	0.12 (0.01-1.31)	
		Dose 2	23	0.85 (0.54-1.33)		6	1.11 (0.47-2.66)	
		Ref.	824		1	134	1	
Females	[0-7]	Dose 1	23	0.76 (0.49-1.19)		6	1.16 (0.46-2.92)	
		Dose 2	20	0.84 (0.53-1.33)		4	1.11 (0.39-3.13)	
		Ref.	655		1	113	1	

SCCS: Self-Controlled Cases Series; n.: number; CI: Confidence interval; Ref.: reference period (unexposed period). *adjusted by calendar period; **excess cases are not given when RI did not show a significant increase of incidence over the [0-21] risk interval